Reuters logo
BRIEF-Galena Biopharma says combination of trastuzumab and NeuVax in HER2 low-expressing patients is well-tolerated
October 10, 2016 / 11:32 AM / a year ago

BRIEF-Galena Biopharma says combination of trastuzumab and NeuVax in HER2 low-expressing patients is well-tolerated

Oct 10 (Reuters) - Galena Biopharma Inc :

* Galena Biopharma Inc - combination of trastuzumab and neuvax in HER2 low-expressing (le) patients is well-tolerated

* Galena Biopharma Inc - cardiac effects of trastuzumab are not impacted by addition of NeuVax

* Galena Biopharma Inc - there was one CG patient who experienced a grade 3 cardiac adverse event during trial

* Galena Biopharma- after 12 months of follow-up combination of trastuzumab and neuvax , co expects to report first interim efficacy,immunologic outcomes at end of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below